Antagonist antibodies targeting LAIR1 promote inflammatory phenotype in myeloid cells and activate lymphocytes

Written By Guest User

Bonnans C. et al. Keystone Symposia on Myeloid Cells and Innate Immunity in Solid Tumors, Virtual. September 21-23, 2020.

Guest User
Previous

LILRB4-targeting Antibody–Drug Conjugates for the Treatment of Acute Myeloid Leukemia
Next

Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells